Issue Archive

COVER FIGURE
Gilteritinib induces morphologic differentiation responses in a subset of patients with clinical responses to it. The bone marrow aspirate shown here, collected from a patient with a differentiation response to gilteritinib, shows a reduction in marrow blast percentage with marked granulocytic hyperplasia with a left shift. In patients with differentiation responses, the FLT3 mutation allelic burden remains elevated throughout the period of clinical response. The aspirate smear shown here is a Wright-Giemsa stain at 500× objective magnification (oil immersion). See the article by McMahon et al.